Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

NCT06620835 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

BIOLOGICAL: Blood samples for Hematology
BIOLOGICAL: Blood samples for Chemistry
BIOLOGICAL: Blood sample for liver function tests
BIOLOGICAL: Pregnancy test
PROCEDURE: Tumour assessment
PROCEDURE: Local Ablative Therapy (LAT)

Sponsor

Groupe Francais De Pneumo-Cancerologie